NEW YORK (360Dx) – The US Food and Drug Administration today issued a warning letter to Magellan Diagnostics that alleges several violations of federal law, including marketing "significantly modified versions" of two blood-based lead testing systems without the FDA's required clearance or approval.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.